AstraZeneca launches health-tech business, Evinova

Betsy Goodfellow | November 21, 2023 | News story | Business Services AstraZeneca, Pharmacy, health-tech 

AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is hoped will become a leading provider of digital health solutions for healthcare professionals, regulators and patients.

The new business has long-term backing from AstraZeneca as well as strategic collaborations with Parexel and Fortrea, both of which have entered into agreements to offer Evinova digital health solutions to their wider customer bases. Evinova is also partnering with Accenture and Amazon Web Services in order to accelerate the industry adoption and expand the global reach of its products.

It is intended that Evinova will “prioritise bringing to market established and scaled digital technology solutions already being used by AstraZeneca to optimise clinical trial design and delivery,” according to AstraZeneca’s press release.

The business aims to reduce the time and cost of developing new medicines while also bringing care closer to home for patients and reducing burden on health systems.

Cristina Duran, president of Evinova, commented: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”

Betsy Goodfellow

Related Content

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) …

AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment

AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in …

AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of …

Latest content